The Patent Finder
BH

Biotissue Holdings Inc.

First filing 2004
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Previously recorded as Tissuetech, Inc. (to 2023)

25 patents currently held

4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2 more records may belong here and await a decision; they are not counted.

The next term ends in May 2027. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
5
Ending by 2030
May 2027
Next term end
16
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents fee due within 90 days all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Amniotic Membrane Preparations and Purified Compositions and Therapy for Scar Reversal and Inhibition US 8,182,840
Cited by 111 later US patents, top 5% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.
Ends Dec 2028 · High confidence
Also notable
Purified Amniotic Membrane Compositions and Methods of Use US 8,153,162
The most cited patent in this portfolio, cited by 196 later US patents, top 5% of utility patents granted in 2012 in our data. Protection runs to 2027.
Ends May 2027 · High confidence
Also notable
Amniotic Membrane Preparations and Purified Compositions and Anti-Inflammation Methods US 8,182,841
Cited by 115 later US patents, top 5% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.
Ends Dec 2028 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Jan 9 to 25, 2027 · next Jan 9
  • 1 fee due Mar 8, 2027
    The maintenance fee for Cell-Free Graft (US 9,125,871) comes due Mar 8, 2027. Unpaid by Sep 8, 2027, it lapses early.
  • 1 fee due Apr 1, 2027
    The maintenance fee for Methods of Processing Fetal Support Tissues, Fetal Support Tissue Powder Products, and Uses Thereof (US 10,426,731) comes due Apr 1, 2027. Unpaid by Oct 1, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 23, 2026
  • 13 terms have ended since Aug 23, 2026

What they patent

The largest of its 16 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 8,153,162Purified Amniotic Membrane Compositions and Methods of Use
In force
 · High confidence
In forceHigh confidence
US 9,006,192RNAi Methods and Compositions for Stimulating Proliferation of Cells with Adherent Junctions
In force
 · High confidence
In forceHigh confidence
US 8,182,841Amniotic Membrane Preparations and Purified Compositions and Anti-Inflammation Methods
In force
 · High confidence
In forceHigh confidence
US 8,182,840Amniotic Membrane Preparations and Purified Compositions and Therapy for Scar Reversal and Inhibition
In force
 · High confidence
In forceHigh confidence
US 9,125,871Cell-Free Graft
held by Biotissue AG
In force
 · Medium confidence
In forceMedium confidence
US 12,397,086Methods of Modulating Bone Remodeling
In force
 · High confidence
In forceHigh confidence
US 10,426,731Methods of Processing Fetal Support Tissues, Fetal Support Tissue Powder Products, and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 9,682,160Methods of Sterilizing Fetal Support Tissues
In force
 · High confidence
In forceHigh confidence
US 8,940,294Methods of Isolating and Culturing Stem Cells
In force
 · High confidence
In forceHigh confidence
US 9,682,044Methods of Processing Fetal Support Tissues, Fetal Support Tissue Powder Products, and Uses Thereof
In force
 · High confidence
In forceHigh confidence
10 of 25 patents shown.
Pro members see all 25.
Pro members: see all 25 patents
Also on record, not counted in the 25: 4 patents in force now held by others · 21 patents ended · 11 applications pending · 1 application abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited